Akeso says its closely watched drug improved patient survival in a lung cancer trial
Posted:
Akeso, a Chinese biotech with a drug positioned to rival Merck’s megablockbuster Keytruda, has reported for the first time that the therapy can improve patient survival.
A new AI framework can detect neurological disorders by analyzing speech with over 90% accuracy. The model, called CTCAIT, captures subtle patterns in voice that may indicate early symptoms of diseases like Parkinson’s, Huntington’s, and Wilson disease.
Read more here.
Attendees
Sponsors and Exhibitors
Agenda 2025
Contact us